ENVB Enveric Biosciences, Inc.
USHealthcareAs of 2026-08-24
Why ENVB matters now
Enveric Biosciences, Inc. (ENVB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.41 with -1.40% on the session and $841.8K in market capitalization; recent performance reads 1-month -39.34% and YTD -64.74%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.6M, and EPS of $-1.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1047.8%.
The latest indexable market news headline is "Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Coveney Kevin Michael filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.38
P/S
0.00
EV/EBITDA
0.51
DCF Value
$12.39
FCF Yield
-1047.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-221.0%
ROA
-148.9%
ROIC
-162.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.6M | $-1.08 |
| Q4 2025 | $0.00 | $-2.2M | $-3.81 |
| FY 2025 | $0.00 | $-12.1M | $-36.24 |
| Q3 2025 | $0.00 | $-1.9M | $-10.81 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.10
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.